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Abstract: Autogenous cancellous bone graft is the current gold standard of treatment for the man-
agement of bone defects since it possesses the properties of osteoinduction, osteoconduction, and
osteogenesis. Xenografts and synthetic grafts have been widely reported as available and low-cost
alternatives, which retain good osteoconductive and mechanical properties. Given the rich biodi-
versity of ocean organisms, marine sources are of particular interest in the search for alternative
bone grafts with enhanced functionalities. The purpose of this paper is to assess the biocompatibility
of a marine-derived bone graft obtained from shark tooth, which is an environmentally sustain-
able and abundant raw material from fishing. This research presents the findings of a preclinical
trial—following UNE-EN ISO 10993—that induced a critical-sized bone defect in a rabbit model and
compared the results with a commercial bovine-derived bone graft. Evaluation by micro-computed
tomography and histomorphometric analysis 12 weeks after implantation revealed good osseointe-
gration, with no signs of inflammatory foreign body reactions, fibrosis, or necrosis in any of the cases.
The shark tooth-derived bone graft yielded significantly higher new bone mineral density values
(54 ± 6%) than the control (27 ± 8%). Moreover, the percentage of intersection values were much
higher (86 ± 8%) than the bovine-derived bone graft (30 ± 1%) used as control. The area of occupancy
by bone tissue in the test material (38 ± 5%) also gave higher values than the control (30 ± 6%). The
role of physicochemical properties, biphasic structure, and composition on the stimulation of bone
regeneration is also discussed.
Keywords: marine bone graft; preclinical trial; calcium phosphate; osseointegration; biomaterial
1. Introduction
Bone grafts offer a mechanical support and a biological function in the treatment of
several pathologies, among these high-grade open fractures with bone loss, high-energy
trauma, non-union or delayed union, resection of bone tumors, infections requiring exten-
sive bone debridement, and secondary bone defects [1]. Opinions diverge as to the most
appropriate bone replacement treatment, when considered from both a clinical and an
economic perspective.
There is a paucity of clinical evidence and controlled studies comparing different
techniques to inform strategies and treatments for critical-sized bone defects. Current
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therapeutic approaches include distraction osteogenesis, first reported by Ilizarov in the
1950s [2], as well as Masquelet’s more recently developed induced membrane technique [3].
Furthermore, the use of bone grafts—autografts, allografts, xenografts, and synthetic
grafts—has been widely communicated. Autogenous cancellous bone graft possesses the
properties of osteoinduction, osteoconduction, and osteogenesis, making it the current
gold standard of treatment for the management of bone defects. Additionally, it is non-
immunogenic and does not carry the risk of transmissible infection [4,5]. However, the
morbidity associated with harvesting the amount of graft required to fill the defect is
substantial [6–8].
In orthopedic surgery, there are situations where synthetic bone substitutes have
the same clinical results as autografts, but with the advantage that they do not consume
surgical time and are not limited in availability. In particular, the development of bone
grafts of natural origin obtained from non-human species has received much attention in
recent decades. Xenografts are mainly derived from bovine, porcine, equine, and marine
sources. These bone grafts can provide structural support and osteoconduction; however,
osteogenesis and osteoinduction are not possible. The fabrication process is based on
heating and chemical treatments leading to the production of hydroxyapatite (HA) and/or
other calcium phosphate compounds. Then, the organic and osteogenic components of the
bone are removed, although the potential risk of disease transmission (bovine spongiform
encephalopathy) is not completely avoided [9]. Xenografts of bovine origin have given
good results in dental and maxillofacial surgeries, but contradictory results have been
achieved in orthopedic surgery, in particular foot and ankle surgery [10,11].
Xenografts obtained from marine sources are of particular interest given the rich
biodiversity of ocean organisms with a similar structure to the human bone, which makes
them suitable bone graft biomaterials with osteoconductive properties. Corals are among
the most studied marine-derived biomaterials. Coral-based biomaterial is mainly calcium
carbonate and can be chemically transformed into HA by a hydrothermal conversion to
increase the strength of the coral skeletons [12]. Current clinical evidence is limited to
well-contained voids in dental and maxillofacial surgery, and to fill bony voids or gaps that
do not affect bone stability in limbs and pelvis [13,14].
In recent years, other marine species have been investigated for use in bone tissue
engineering: nacre, seashells (foraminifera; bivalve mollusks such as oysters and mussels),
sponge skeletons, diatom frustules, sea urchin spines, cuttlefish bone, and other fish bones
such as tuna [15]. Calcium carbonate predominates in most of these sources, except for
certain sponge skeletons namely Demonspongiae and Hexactinellida and diatom frustules,
which are based on silicon compounds [16].
Marine sources with a calcium phosphate composition are also under investigation.
One of these, the subject of this study, is shark tooth from two commercial species, Isurus
oxyrinchus and Prionace glauca. Shark tooth is gaining increasing recognition as a promising,
eco-friendly source of bioapatites: it is an abundant by-product of fishing, is environmen-
tally sustainable, and disease transmission risk from the marine ecosystem has not been
reported. Preliminary in vitro [17] and in vivo evaluations [18] of these marine-derived
grafts have confirmed good results for bone regeneration.
In this paper, we present the results of a preclinical trial of this marine-origin bone
graft obtained from shark teeth, by means of a critical-sized bone defect test in an animal
model. We carried out the biological evaluation and assessed biocompatibility according to
UNE-EN ISO 10993: 2007 part 6. The purpose of this study was to gather initial findings
on the potential of shark tooth-derived bone graft for the treatment of critical-sized bone
defects, and to identify areas of focus for future research.
2. Material and Methods
2.1. Shark Tooth-Derived Bone Graft Processing Method
The marine-origin bone graft under evaluation was obtained from shark teeth of the
Prionace glauca and Isurus oxyrinchus species provided by COPEMAR S.A. (Vigo, Spain).
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The manufacturing method was similar to that described by López-Álvarez et al. [17,18],
involving pyrolysis up to 1100 ◦C for 12 h, followed by grinding and sieving to select the
desired grain size fraction, in this case granules with diameters between 0.5 and 1.0 mm.
Finally, the graft material was packed in laminar flow cabins and sterilized by a 25 kGy
dose of gamma radiation.
To determine the composition and structure of the shark tooth-derived bone graft,
physicochemical characterization was performed using inductively coupled plasma optical
emission spectrometry (ICP-OES, using a Perkin Elmer Optima 4300 DV), complemented
by ion chromatography (DIONEX ICS-3000), Fourier-transform Raman spectroscopy (FT-
Raman, using a Bruker RFS100 equipped with an Nd:YAG laser), and X-ray diffraction
(with a Siemens D-5000 diffractometer).
Bio-Oss® (Geistlich Pharma AG, Wolhusen, Switzerland), composed of lyophilized
anorganic bovine bone granules with a granule size ranging from 0.25 to 1.0 mm, was
used as a control bone graft. It is a reference xenograft used in dental bone regeneration
worldwide and has granules of a similar shape and size to those in the test sample (i.e., the
shark tooth-derived bone graft).
2.2. Animal Model
Ten male New Zealand White rabbits were supplied by a qualified laboratory animal
supply center (La Granja cunícola San Bernardo, S.L., Tulebras, Navarra), and were quaran-
tined for 3 weeks prior to commencement of the study. They were aged between 18 and
21 weeks and weighed between 3.7 and 4.0 kg.
The animals were housed in individual enriched cages in the Animal Experimentation
Service Facility of the University of Santiago de Compostela (Lugo, Spain) following ethical
approval (procedure code: 03/18/LU-002) as a randomized controlled trial with one inter-
subject control. Conditions such as temperature (15–21 ◦C), humidity, air renewal, and
cycle time (12 h alternating cycles of light and dark) were controlled according to Annex
II of Directive 86/609/EEC. The animals were fed with dry feed prepared in the form of
pellets, sterilized and specially manufactured for the feeding of laboratory animals. The
center’s head of animal welfare, along with staff and the researchers, watched over the
health of the animals throughout the experiment. There were no unexpected deaths.
After a quarantine, animals were premedicated with ketamine 25 mg/kg/IM (Ketamidor®
100 mg/mL; Richter pharma AG, Wels, Austria), medetomidine 50 µg/kg/IM (Sededorm®
1 mg/mL; Vetpharma Animal Health SL, Barcelona, Spain), and buprenorphine 0.03 mg/kg
(Bupaq® 0.3 mg/mL; Richter pharma AG). The anesthesia was maintained by the inhala-
tion of an O2 and 2% isoflurane (Vetflurane; Virbac SA, Caro, France) mixture using a
facemask.
After aseptic preparation of the skin, a lateral approach of the distal femur was per-
formed, affecting the skin and subcutaneous tissue to subsequently dissect the musculature
and expose the surface of the lateral femoral condyle with a periosteal elevator. A 6 mm
defect was created using a trephine connected to a surgical motor INTRAsurg® 300 (KaVo,
Biberach, Germany). Once the biomaterial was placed, in the lateromedial direction, the
wound was sutured using 4–0 vicryl in deep planes and 3–0 nylon for the skin. The control
biomaterial was placed in the contralateral limb following the same procedure. The 2 types
of biomaterial were randomly assigned a total of 5 times to both the left and right sides
based on a computer-generated randomization list.
After wound closure, the skin was soaked with povidone solution. After the surgical
intervention, atipamezole (0.15 mg/kg/IM; Nosedorm® 5 mg/mL; Vetpharma Animal
Health SL) was administered to reverse the effects of the medetomidine. The animals were
monitored and returned to their accommodation, where they remained throughout the
experimental period.
After the surgeries, pain was controlled with buprenorphine (0.01–0.03 mg/kg/IM,
Bupaq® 0.3 mg/mL; Richter pharma AG) for 3 days and with meloxicam (0.2 mg/kg/SC,
Metacam, Boehringer) for 5 days. As a prophylactic antibiotic, we used enrofloxacin
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(5 mg/kg/12 h, Syvaquinol® 10% Oral Solution; Syva labs) for 3 weeks. In addition, the
condition of the wounds was evaluated twice a week, and the cages were cleaned each
time.
A bone graft was placed in each distal femur of all animals. In other words, a total
of 20 bone grafts were placed in the 10 animals—2 different bone grafts per animal. To
avoid errors due to the implantation side, 5 bone grafts of each type (test or control) were
placed in the left femurs, and 5 of each type in the right femurs. The trial period used was
12 weeks.
The animals were sacrificed with an overdose of intravenous sodium pentobarbital
(Dolethal 200 mg/mL, Vetoquinol) after sedation with ketamine 25 mg/kg + medetomidine
50 µg/kg + buprenorphine 0.03 mg/kg. Subsequently, the distal femurs were recovered
by dissection and the use of a bone saw. Specimens were immediately immersed in a 10%
buffered formalin solution for a minimum of 2 weeks until the time of processing. For
identification, we used a code consisting of a number and a letter. The number indicated
the animal (from 1 to 10) and the letter the side of the femur (right-R and left-L). All bone
grafts were recovered.
2.3. Histological Preparation
Once fixed, the samples were dehydrated in increasing ethanol concentrations (80%,
96%, 100%, and 100%) under agitation. The inclusion was carried out using a photopolymer-
izable resin based on glycolmethacrylate at increasing concentrations (Technovit 7200 VLC,
Kulzer, Germany). Polymerization took place through the use of high-intensity blue light
with specific equipment. The undecalcified blocks obtained were prepared for analysis by
microtomography and were subsequently sectioned for histology.
2.4. Micro-Computed Tomography
The samples were scanned using a high-resolution Micro-CT Skyscan 1172 scanner
(Bruker MicroCT NV, Kontich, Belgium) located at the A Graña Marine Biology Station
in Ferrol, A Coruña (University of Santiago de Compostela). The parameters used for
scanning were the following: the X-ray source was set at 100 kV and 100 µA with a voxel
size of 13.58 µm, using a 0.5 mm Al/0.08 mm Cu filter. The scanning was performed over
a 360◦ rotation acquiring images every 0.4◦. Once scanned, the images were reconstructed
with NRecon® software (Bruker MicroCT NV, Kontich, Belgium) using the algorithm
described by Feldkamp (Feldkamp, Davis, and Kress, 1984). In all cases the parameters
were optimized to reduce image noise and possible artifacts. They were then reconstructed
with histogram parameters (dynamic range) from 0 to 0.038 for all images, regardless of the
material used. Reconstructed images were evaluated with Data Viewer® software (Bruker
MicroCT NV, Kontich, Belgium) once the implant was perfectly aligned. For the analysis
of the percentage of biomaterial in the volume of interest (VOI), 2 different VOIs were
defined:
1. VOI 1 (large VOI or 6 mm VOI). As the defect made in the animals was 6 mm, this
distance was taken as a reference, creating a circular VOI of 6 mm in diameter and
placing the bone graft in the center of that circle.
2. VOI 2 (small VOI). A cylindrical VOI was manually profiled around the whole contour
of the material.
Additionally, the percentage of intersection was defined, corresponding to the per-
centage of bone graft that is in contact with bone. VOI 1 (6 mm diameter) was used for
this analysis. The percentage of binarized pixels was determined as material that was in
contact with binarized pixels as bone, using CTAn® software (Bruker MicroCT NV, Kontich,
Belgium).
2.5. Histological and Histometric Analysis
After the microtomography analysis, the samples were subjected to sectioning and
microgrinding techniques using machinery from the Exakt system (Exakt Apparatebau,
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Hamburg, Germany). The polymerized blocks were prepared, obtaining 2 sections per
sample, which were reduced to a thickness of about 40 µm. The thin sheets were stained
with Levai-Laczkó dye, which makes it possible to distinguish between lamellar and newly
formed bone, and also to maintain the matrix-cellular bone architecture that is essential for
the subsequent histomorphometric evaluation.
The histological evaluation was performed by semi-quantitative evaluation techniques
according to Annex E, table E.3 of ISO 10993-6: 2007. This evaluation estimates the degree
of compatibility of the bone graft in relation to a recognized control. Two independent
and experienced observers blinded to the treatments performed the scoring. From the
quantification of cellular observations, by counting the number of various cells per high-
power field, the irritant assessment was recorded as non-irritant (for values from 0.0 up to
2.9), slight irritant (from 3.0 up to 8.9), moderate irritant (9.0 up to 15.0), and severe irritant
(>15).
The histometric analysis was performed by trained staff who did not know what
material was being analyzed. The images were captured using an optical microscope
(BX51, Olympus, Tokyo, Japan) connected to a digital color camera (DP71, Olympus, Tokyo,
Japan) equipped with a motorized plate (Märzhäuser, Steindorf, Germany). The images
were aligned and connected automatically to obtain complete images of the bone and the
implanted biomaterial at a magnification of ×40.
From the histological images, the proportions occupied by bone, bone graft and soft
tissue were identified using a digitizing tablet (Cintiq Companion, Wacom, Germany),
colored (Photoshop, Adobe, San Jose, CA, USA), and digitally measured using an image
analysis program (CallSens, Olympus, Tokyo, Japan).
2.6. Statistical Analysis
The results of the microtomographic and histometric analysis are reported as mean
and standard deviation values (n = 10). The differences between groups were statistically
analyzed using a paired Student’s t-test for each of the variables. p-values < 0.05 were
considered to be statistically significant. Data were represented in box plots (minimum,
25% percentile, median, 75% percentile, maximum).
3. Results
3.1. Shark Tooth-Derived Bone Graft Physicochemical Characterization
ICP-OES was used to determine the elemental composition of the shark tooth-derived
bone graft and identified a calcium phosphate compound with the presence of minor
elements such as sodium (Na) (1.25 ± 0.02 wt%) and magnesium (Mg) (0.54 ± 0.02 wt%),
as well as other trace elements such as strontium (Sr), potassium (K), aluminum (Al), and
iron (Fe). Ion chromatography also detected the presence of a relevant amount of fluorine
(F) (1.05 ± 0.11 wt%).
(Fourier-transform) FT-Raman analysis was carried out to evaluate the composition
of the calcium phosphate in terms of functional groups (Figure 1A). Raman peaks were
detected at 1070, 960 and 430 cm−1, attributed respectively to asymmetric stretching,
symmetric stretching, and symmetric bending of PO4−3 groups [19]. A peak at 588 cm−1
attributed to asymmetric bending of PO4−3 was also detected. Moreover, asymmetric
stretching of CO3−2 groups was detected at 1064 cm−1 [19]. The absence of the Raman
bands associated with organic compounds from the original raw material, including those
attributed to amide III (1271 cm−1), C-H2 groups of lipids and some proteins (1450 cm−1),
and amide I (1665 cm−1), proves the efficiency of the thermal processing to obtain anorganic
compounds [20,21].
The structural evaluation of the calcium phosphate, performed by X-ray diffractometer,
found the characteristic X-ray diffraction pattern of a crystalline material (Figure 1B). The
calcium phosphate structure was established on a combination of apatitic and non-apatitic
phases. In the case of apatitic phases, peaks attributed to an apatite-(CaOH) (including
hydroxyapatite, Ca5(PO4)3OH and apatite-(CaF) (H0.6Ca5F0.4O12.6P3)) and a fluorapatite
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(Ca5(PO4)3F) were found in a semi-quantified percentage of around 70% of the total
composition. The non-apatitic phases were attributed to tricalcium bis (orthophosphate)
(Ca3O8P2) and whitlockite (Ca18Mg2H2(PO4)14) in a semi-quantified percentage of around
30% [17,18].
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Figure 1. (Fourier-transform)FT-Raman spectra (A) and X-ray diffractogram pattern (B) of calcium
phosphate derived from shark tooth (P. glauca and I. oxyrinchus).
3.2. Histological and Histometric Analyses
For the histological assessment, semi-quantitative evaluation techniques were used to
quantify the different inflammatory cells, as well as the formation of new blood vessels
and the presence of fibrosis and fatty infiltrate.
Optical images of shark tooth-derived bone graft and Bio-Oss® samples show that
macroscopically both specimens presented a normal anatomy, with no signs of bone
alteration (Figure 2). Normal bone tissue is seen in contact with both types of bone
grafts. Inflammation and fibrosis were not considered significant or incompatible with the
osseointegration of both grafts. No changes in tissue morphology were observed. Also, no
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inflammatory cells, traumatic necrosis, foreign debris, fatty infiltrate, or granulomas were
observed, which demonstrates high biocompatibility in both the tested and control bone
grafts.
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magnification 4× (A,B), and higher magnification (C,D).
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The most relevant semi-quantitative histological data are depicted in Table 1. Cellular
observations were quantified by counting the number of various cells per high-power
field. The cellular response (presence of polymorphonuclear cells, giant cells, plasma
cells, lymphocytes, and macrophages) in the test sample has a score of 0 or 1, denoting
respectively the absence or presence of fewer than 5 per high-power field. No necrosis was
observed in the test sample. Fibrosis (1 moderately thick band and 2 narrow bands) was
observed in 3 of the 10 test samples (4R, 5R and 6L) but was not statistically significant.
Information on vascularity was obtained by counting the number of capillaries per high-
power field (400×). There was no evidence of neovascularization or fatty infiltrate. With
the data shown here we can conclude that, under the conditions of our study, the shark
tooth-derived bone graft is as “non-irritant” to the tissue as the Bio-Oss® control sample.
Table 1. Semi-quantitative histological evaluation at 12 weeks post implantation in the test group (shark tooth-derived bone
graft) and in the control group (Bio-Oss®).
Test Sample Control Sample
Animal Number 1R 2R 3R 4R 5R 6L 7L 8L 9L 10L 1L 2L 3L 4L 5L 6R 7R 8R 9R 10R
Inflammation
Polymorphonuclear 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
Lymphocytes 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Plasma cells 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Macrophages 1 1 1 1 1 1 0 1 1 0 2 2 0 0 0 0 0 0 0 1
Giant cells 0 1 1 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
Necrosis 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Sub-Total (×2) 1 2 2 1 1 2 0 1 1 0 2 4 0 0 0 0 0 0 0 1
Neovascularization 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
Fibrosis 0 0 0 2 1 1 0 0 0 0 3 2 0 0 0 0 0 0 0 2
Fatty infiltrate 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Sub-Total 0 0 0 2 1 1 0 0 0 0 3 3 0 0 0 0 0 0 0 2
Total 1 2 2 3 2 3 0 1 1 0 5 7 0 0 0 0 0 0 0 3
Group Total 15/10 = 1.5 15/10 = 1.5
Average TEST (-) CONTROL = 1.50 − 1.50 = 0.00 (0)
Traumatic necrosis 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Foreign debris 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 2 2 2 3
No. sites examined The whole contour of the biomaterial
In relation to the histometric evaluation, Figure 3 shows typical optical images of
the shark tooth-derived bone graft samples before and after the digital coloring and
analysis. After coloring, the image analysis program automatically detected the areas of
color corresponding to the identification of bone tissue, biomaterial, and connective tissue.
From this value, the percentages of bone graft and bone tissue were calculated (Figure 4).
As observed, shark tooth-derived bone graft samples showed higher density of bone
graft (biomaterial) and bone tissue in the volume of interest (43 ± 6% and 38 ± 5%) when
compared with the control group (28 ± 5% and 30 ± 6%). The cause of these differences
in bone graft density could be due to the grain size (0.5–1 mm in the test and 0.25–1 mm
in the control), which generated a larger occupied area of shark tooth-derived bone graft.
The difference in the bone percentages may indicate that shark tooth-derived bone graft
allows osteoconduction to take place more effectively. Both differences were statistically
significant.
Appl. Sci. 2021, 11, 2116 10 of 15
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3.3. Microtomographic Evaluation
The micro-computed tomography analysis found the percentage area occupied by the
bone tissue, the bone graft + bone tissue, and the intersection percentage of the bone graft
with bone tissue (Figure 5). These values were carefully analyzed due to the difficulty in
detecting the control material in the tomographic image, because the Bio-Oss® presented a
density similar to that of bo e tissue. In both cases, the perc ntage of bone graft occupancy
was similar: 34 ± 7% for the test and 28 ± 7% for the control. Nevertheless, th re was a
significant increase in the area occupied by the bone tissue in the test samples (54 ± 6%) in
relation to the control samples (27 ± 8%). Moreover, the percentage of intersection bone
graft-bone tissue seems to be favored by the shark tooth-derived bone graft, reaching very
high values (86 ± 8%) when compared with the control (30 ± 1%).
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4. Discussion
Research into shark tooth-derived calcium phosphate compounds with traces of F,
Na and Mg ions marks a recent development in the treatment of bone defects [17]. The
crystalline structure of this bone graft is a combination of an apatitic phase (65–70%),
including hydroxyapatite and fluorapatite, and a non-apatitic phase (35–30%), mainly
whitlockite.
Preliminary in vitro studies have shown that this biphasic marine bone graft promotes
the proliferation of MC3T3 preosteoblasts after 21 days of incubation and results in a
significant increase in osteogenic activity (p < 0.01) [17]. Moreover, in vivo assays in a rodent
model demonstrated an excellent osseointegration grade 3 weeks after implantation, with
significantly higher bone mineral density (p < 0.05) than commercial synthetic HA/TCP
bone graft (60%/40%) [18], and potential osteoconductive properties, due to the porous
morpholo y and th formation of intergranular cavities which allowed the ingrowth of
new bone tissue cells.
Bioma erials for clinical applications are subject to the strict requirements set out in ISO
10993-6:2007 (E), which specifies “test methods for the assessment of the local effects after
implantation of biomaterials intended for use in m dical device ”. The purpose of such
tests is to establish the safety and efficacy of the bio aterial in a biological environment, to
ensure that it does not gen rate adv rse reactions or release toxic substances.
Our study demo strated the biocompatibility of marine-origin b e graft obtained
from shark teeth. The preclinical trial carried out on cr tical femoral defects in rabbits
showed a non-irritant behavior and revealed that the test group (marine-origin bone graft)
presented greater osseointegration at 12 weeks than the control group (bovine-origin bone
graft). R sults from the histological analysis showed a higher area of occupancy by bone
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tissue in the test material (38 ± 5%) than in the control (30 ± 6%). Additional evaluation
by micro-CT analysis confirmed this finding, given that values for bone mineral density
were statistically higher in the test group (54 ± 6%) than in the control group (27 ± 8%).
Moreover, the measurement of the bone graft-bone tissue intersection was much higher for
the shark tooth-derived bone graft (86 ± 8%) than the control (30 ± 1%). While these figures
confirm the superiority of the test bone graft in terms of bone formation and intersection
measurements, the actual microtomographic values are likely to be overestimated, probably
due to the similar radiological characteristics of the control sample and the bone tissue. This
fact would also explain the large differences in the percentage of intersection. Nevertheless,
taken as a whole, the results of the histometric and microtomographic analysis support
the conclusion that the specific composition and structure of this marine-origin bone graft
plays a key role in the promotion of bone regeneration.
The presence of fluor in the form of fluorine in the marine bone graft composition
participates in the biochemical processes that enhance the synthesis of growth factors in
bone cells, contributing to the differentiation of osteoprogenitor cells [22] and also to bone
consolidation and regeneration [23]. In the form of fluorapatite, this element promotes a
more crystalline and therefore more stable apatite [24], improving the mechanical properties
with respect to hydroxyapatite. The non-apatite phase, on the other hand, is less crystalline
and therefore less stable, allowing some degree of resorption.
The incorporation of Mg in the form of whitlockite is also of interest because of its
influence on the synthesis of parathyroid hormone, which regulates bone homeostasis [25].
Furthermore, the presence, albeit to a lesser extent, of other ions such as Na, Sr and K
contributes to cell adhesion and decreases osteoclastic activity [26].
Our findings further confirm shark tooth-derived bone graft as a good alternative
to other bone xenografts on the market. Its clinical applications are not only limited to
small bone defects, namely dental surgeries, but can be extended to the field of orthopedic
and traumatological surgery, where there are clinical situations requiring high amounts of
bone graft for the treatment of critical-sized bone defects. Future clinical assays would be
necessary to assess its application in larger bone defects.
5. Conclusions
This preclinical evaluation demonstrates the biocompatibility and suitability of shark
tooth-derived bone graft for the treatment of critical-sized bone defects. Under the con-
ditions of this study, the test bone graft exhibited an adequate biological response, with
no signs of inflammatory foreign body reactions, fibrosis, or necrosis in any of the cases
12 weeks after implantation.
Results from histological techniques and microtomographic analysis revealed good
osseointegration, with bone mineral density and percentage of intersection values superior
to the bovine-derived bone graft used as a control.
The biphasic structure, with both an apatitic (65–70%) and non-apatitic (35–30%)
phase, as well as the specific composition of the shark tooth-derived bone graft, mainly
calcium phosphates enriched with F and Mg, may be important factors stimulating bone
regeneration.
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